Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Mymetics Corporation (MYMX)

Add MYMX Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, MERCURIAL, corpus, MADDSTACKER, MrCheap
Search This Board: 
Last Post: 10/21/2017 10:47:40 PM - Followers: 62 - Board type: Free - Posts Today: 0




Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands. Focused on developing next generation preventative vaccines for infectious diseases. Mymetics core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.

Mymetics currently has 5 vaccines in its pipeline:
Intranasal Influenza


Current Share Structure:

Oustanding Shares: 303.7 million (11/2016 & no change since 2012)
Floating Shares: 91.1 million*  (a/o 03/29/16)
* verified by TA (

Current Market Cap (12/7/16): $5.0 million
Enterprise Value: N/A

*Enterprise value can be thought of as the theoretical takeover price if the company were to bought. In the event of such a buyout, an acquirer would generally have to take on the company's debt, but would pocket its cash for itself. EV differs significantly from simple market capitalization in several ways, and many consider it to be a more accurate representation of a firm's value.


Mymetics Starts Research Project with Sanofi for Influenza Vaccines

Dec 01, 2016
OTC Disclosure & News Service

EPALINGES, Switzerland, Dec. 1, 2016

EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.

"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics. "We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines."

About Mymetics
Mymetics Corp. (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya,  and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.

Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including projects with Sanofi, PATH-MVI and the Bill and Melinda Gates Foundation.

For further information, please visit




Intellectual  Property

WO/1999/025377 (GP41 mutee) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection Mymetics Corp. Expiration date: November 16, 2018
WO/2005/010033 (GP41 ter) New soluble and stabilized trimeric form of GP 41 polypeptide Mymetics Corp. Expiration date: July 28, 2024
WO/2007/099446 (Virosome-P1) Virosome-like vesicles comprising gp41 - derived antigens Mymetics Corp. + INSERM + Pevion Expiration date: January 3, 2027

US/61/202 215 (GP41 4th gen) Mymetics Corp. Expiration date: February 5, 2029
US/61/202 219 (Splitting GP41) Mymetics Corp. Expiration date: February 5, 2029
WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides, peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp. Expiration date: June 1, 2024
WO/2004/078099 (AMA49) Compositions and methods for the generation of immune response against Malaria Mymetics Corp. Expiration date: March 2, 2023
WO/2004/045641 (APRECS) Antigen-complexes Bestewil BV Expiration date: November 19, 2023
WO/2004/110486 (Lipopeptide) Functionally reconstituted viral membranes containing adjuvant Bestewil BV Expiration date: June 17, 2024
WO/2004071492 (DCPC) Virosome-like particles Bestewil BV Expiration date: December 2, 2023
  [Viruses that can be applied and used in the formation of the virosome-like-particles according to the invention can be derived from all sorts of viruses, non-limiting examples of     such viruses being: Retroviridae such as Human Immunodeficiency virus (HIV); rubellavirus; paramyxoviridae such as parainfluenza viruses, measles, mumps, respiratory syncytial virus, human metapneumovirus; flaviviridae such as yellow fever virus, dengue virus, Hepatitis C Virus (HCV), Japanese Encephalitis Virus (JEV), tick-borne encephalitis, St. Louis encephalitis or West Nile virus; Herpesviridae such as Herpes Simplex virus, cytomegalovirus, Epstein-Barr virus; Bunyaviridae; Arenaviridae; Hantaviridae such as Hantaan; Coronaviridae; Papovaviridae such as human Papillomavirus; Rhabdoviridae such as rabies virus. Coronaviridae such as human coronavirus; Alphaviridae, Arteriviridae, filoviridae such as Ebolavirus, Arenaviridae, poxyiridae such as smallpox virus, and African Swine Fever virus.]               ,901,920.PN.&OS=PN/7,901,920&RS=PN/7,901,920



Virosomes: A Novel Strategy for Drug Delivery and Targeting


Virosomes are reconstituted viral envelopes that can serve as vaccines and as vehicle for cellular delivery of macromolecules. The prospect of drug delivery and targeting using virosomes is an interesting field of research and development. Because virosomes are biocompatible, biodegradable, nontoxic, and non-autoimmunogenic, attemps have been made to use them as vaccines or adjuvants as well as delivery systems for drugs, nucleic acids, or genes for therapeutic purposes. Influenza virus is the most common virus of choice. The success of virosomal drug delivery depends on the methods used to prepare the encapsulated bioactive materials and incorporate them into the virosomes, as are characterization and formulation of the finished preparation. Virosome technology could potentially be used to deliver peptides, nucleic acids or genes, and drugs like antibiotics, anticancer agents, and steroids.

Promising drugs are often discontinued during development because they cannot be suitably delivered to target cells, tissues, and organs. The new generation of therapeutics against cancer or neurodegenerative disorders require delivery systems that target drugs to specified cell types and host tissues by receptor-mediated uptake and contolled release. Virosomal technology presents a novel sophisticated delivery system to meet these challenges.

Virosomes are reconstituted viral envelopes, including membrane lipids and viral spike glycoproteins, but devoid of viral genetic material. The external surface of the virosome resembles that of a virus particle, with spike proteins protruding from the membrane, but their interior compartment is empty. Because virosomes display viral envelope glycoproteins, which, in their native conformation stimulate humoral responses, they are highly effective as vaccine antigens and adjuvants.10-12. Moreover, since the receptor-binding and membrane-fusion properties of the viral envelope glycoprotein can be preserved, virosomes can be used as transport vehicles for cellular delivery of biologically active macromolecules.

Overall, virosomes protect pharmaceutically active substances from proteolytic degradation and low pH within endosomes, allowing their contents to remain intact when they reach the cytoplasm.This is the major advantage of virosomal carrier systems over other drug-delivery vehicles, including liposomal and proteoliposomal carrier systems.


Advantages of Virosomal Drug Delivery

         Virosomal technology is approved by the FDA for use in humans, and has a high safety profile
         Virosomes are biodegradable, biocompatible, and non-toxic12
         No disease-transmission risk
         No autoimmunogenity or anaphylaxis10
         Broadly applicable with almost all important drugs (anticancer drugs, proteins, peptides, nucleic acids, antibiotics, fungicides)
         Enables drug delivery into the cytoplasm of target cell
         Promotes fusion activity in the endolysosomal pathway
         Protects drugs against degradation


Virosomal Structure and Modifications

Image result for influenza virosome images

Figure 1: Virosomes are reconstituted influenza virus envelopes devoid of inner core and genetic information

Virosomes are spherical unilamellar vesicles with a mean diameter of around 150 nm. Influenza virus is most commonly used for virosome production. Virosomes cannot replicate but are pure fusion-active vesicles. In contrast to liposomes, vorosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA) are intercalated within the phospholipid bilayer membrane (Figure 1). Further characteristics of virosomes depend on the choice of bilayer components. Virosomes can be optimized for maximal incorporation of the drug, or for the best physiological effect by modifying the content or type of membrane lipids used. It is even possible to generate carriers for antisense-oligonucleotides or other genetic molecules, depending on whether positively or negatively loaded phospholipids are incorporated into the membrane. Various ligands, such as cytokines, peptides, and monoclonal antibodies (MAbs) can be incorporated into the virosome and displayed on the virosomal surface. Even tumor-specific monoclonal antibody fragments (Fab) can be linked to virosomes to direct the carrier to selected tumor cells.1,11


Drug-Delivery Approaches

Bioactive drug compounds can be entrapped in the aqueous interior of the virosome or in the lipid membrane of the virosome for facilitated entry of the compounds into the cells.19

Virosomes are particularly useful for delivering nucleic acids or genes. These compounds are delivered into the host cell cytoplasm on fusion of the virosome with the endosome or plasma membrane.20  Nucleic acids or genes encoding a naturally occuring protein can be introduced into host cells and can be expressed, provided that the expression cassette contains the proper cis-acting regulatory elements.20,21

Drugs or nucleic acids can be incorporated into the virosome at the time of virosome preparation. The bioactive compound is typically added to the lipid-HA containing solution following removal of the nucleocapsid. Alternatively, the bioactive compound is initially incorporated into a liposome, which is then fused with a virosome containing two hemagglutinins with different pH thresholds to form a virosome-liposome hybrid.22

Proteins also can be delivered to cells via virosome. For example, the gelonin subunit A of diphitheria toxin and ovalbumin have also been successfully delivered  by virosome to target cells.15,22,23  Virosomes carrying peptides derived from the influenza nucleoprotein or intact ovalbumin induced strong cytotoxic T lymphocyte responses, which suggests that the encapsulated peptides and proteins gained access to the cytoplasm.24,25


Targeted Drug Delivery

Ideally one would like to be able to target drug delivery to selected tissues. One can tailor virosomes to targets by incorporating specific molecules (e.g. Fab fragments and ligands) into the virosome's composition. The feasibility of targeted delivery of anticancer drugs by means of virosomal carrier has been demonstrated recently by two independent approaches. In one, a MAb cross-linked to the surface of virosomes mediated specific targeting of the virosomal carrier containing an anticancer drug (e.g. doxorubicin) to human cancer cells. MAbs can bind specifically to cancer-related antigens, providing a means to target systemically administered virosomes to cancerous tissues. Alternatively, ligands that bind surface receptors on the target cells also can be bound to the virosomes to achieve targeted drug delivery. Tumors of mice treated with targeted drug-loaded virosomes failed to grow, and mortality of these animals was significantly reduced. These positive results will definitely open a new field of applications for virosomal technology.18,19


Administration of Virosomes

Several formulations have been reported. Generally, virosomes are suspended in buffered saline (135-150 mMNaCl), but other suitable vehicles also exist. These compositions should be sterilized by conventional liposomal sterilization techniques, such as membrane filtration. The formulation also generally contains auxillary substances as required to stimulate physiological conditions, such as buffering agents and isotonicity adjusting agents (sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride).12,17  The concentration of virosomes used in the vehicle ranges from 20-200mg/ml. These concentrations are varied to optimize treatment with different virosome components or for particular purposes.19

The virosomes are administered in a variety of parenteral routes, including intravenous, intramuscular, subcutaneous, inta-arterial, and inhalable delivery. In addition, virosomes can be administered topically, orally, or transdermally. The virosomes also can be incorporated into implantable devices for long-term release.19,21,22


Authors :  Mazumder B., Bhattacharya S.

1.    Almeida JD, Brand CM, Edwards DC, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 1975; 2:899-901
10.  Gluck R, Mschler R, Finkel B, Que JU, Scarpa B, Cryz SJ. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet, 1994;344:160-3
11.  Huckriede A, Bungener L, Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J. Influenza virosomes: combining optimal presentation of hemagglutinin with                  
       immunopotentiating activity. Vaccine, 2003;21:925-31
12.  Huckriede A, Burgener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. The virosome concept for influenza vaccines. Vaccine 2005;23(s1):S26-38
15.  Bron R, Ortiz A, Wilschut J.  Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (Virosomes). Biochem, 1994;33:9110-17
17.  Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM. The virosome concept for influenza vaccines. Vaccine. 2005;23:S26-38
18.  Felnerova D, Viret JF, Gluck R, Moser C.  Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15:518-29
19.  Cusi MG.  Application of influenza virosomes as a delivery system. Human Vaccines. 2006;2:1-7
20.  Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J.  Virosomes for antigen and DNA delivery.  Adv Drug Deliv. Rev.2005;57:451-63
21.  Sarkar DP, Ramani K, Tyagi SK.  Targeted gene delivery by virosomes.  Methods Mol Biol. 2002;199:163-73
22.  Schoen P, Chonn A, Cullis PR, Wilschut J, Scherrer P.  Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene 
       Ther. 1999;6:823-32.





OTC Disclosure & News Service

Release Date Title Type
Dec 1, 2016 Mymetics Starts Research Project with Sanofi for Influenza Vaccines Press Release
Sep 19, 2016 Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development Press Release
Apr 11, 2016 Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute Press Release
Apr 5, 2016 Mymetics Announces Successful Preclinical Results With Malaria Transmission-Blocking Vaccine Candidate Press Release
Jan 28, 2016 Mymetics Announces Discontinuation of the RSV Collaborative Project Press Release
Apr 20, 2015 Mymetics' led consortium awarded Euro 8.4 million to develop thermo stable and cold chain independent vaccines Press Release
Jan 2, 2015 OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 2 Announcement
Nov 18, 2014 Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate Press Release
Sep 29, 2014 Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute Press Release



Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MYMX News: Quarterly Report (10-q) 08/10/2017 02:01:13 PM
MYMX News: Amended Quarterly Report (10-q/a) 05/18/2017 10:36:07 AM
MYMX News: Quarterly Report (10-q) 05/11/2017 01:13:48 PM
#3935  Sticky Note Correction, DD says that would be 200 Million+.. TheHungryHippo 09/23/17 11:16:00 AM
#3655  Sticky Note Mymetics to Present New Preclinical Data on Thermostable MERCURIAL 09/13/17 08:36:40 AM
#2985  Sticky Note ***NEWS FLASH*** Released Today!!! <<< Catalent, our MACIVIVA corpus 08/10/17 04:13:51 PM
#1310  Sticky Note FEB:2016 Other companies announcing plans to either join TheHungryHippo 05/04/17 09:26:13 AM
#834  Sticky Note <<< MACIVIVA UPDATE>>>(RePost) corpus 03/30/17 02:07:47 PM
#4767   Puerto Rico’s massive pharmaceutical manufacturing industry Work Harder 10/21/17 10:47:40 PM
#4766   Just me but, I'd make sure Work Harder 10/21/17 09:34:36 PM
#4765   Stick around with us Dub, with the right TheHungryHippo 10/20/17 03:40:58 PM
#4764   Lol I still think I can get a better Dubster watching 10/20/17 03:36:31 PM
#4763   Well I bought your shares last time. TheHungryHippo 10/20/17 03:32:51 PM
#4762   I grabbed a bunch but now it's just Dubster watching 10/20/17 03:29:33 PM
#4761   If Sanofi pass on this Virosome Technology of bow-tie 10/20/17 12:48:56 PM
#4760   I feel the same. I have never been TheHungryHippo 10/20/17 12:26:17 PM
#4759   My gut on this is tere is news tyfoidhana 10/20/17 12:24:44 PM
#4758   Well technically speaking the good news is.. TheHungryHippo 10/20/17 11:48:58 AM
#4757   Im in good company glad your here. tyfoidhana 10/20/17 10:48:44 AM
#4756   Im with you. TheHungryHippo 10/20/17 10:34:47 AM
#4755   And that will be on news. So for tyfoidhana 10/20/17 10:33:34 AM
#4754   Yes, There are naked short mm's TheHungryHippo 10/20/17 10:30:35 AM
#4753   Is this referring to MM action? tyfoidhana 10/20/17 10:28:38 AM
#4752   :) No worries. Bring that news! $MYMX MERCURIAL 10/20/17 10:27:49 AM
#4751   the cloud and the 50 day MA to TheHungryHippo 10/20/17 10:24:25 AM
#4750   just woke up.. I agree with SP1 .. TheHungryHippo 10/20/17 10:22:55 AM
#4749   What % of this do you believe to tyfoidhana 10/20/17 10:20:52 AM
#4748   Definite naked shorting going on here Staypositive1 10/20/17 10:07:01 AM
#4747   MMs getting desperate? .062 on ask pre-market. Some BS MERCURIAL 10/20/17 09:23:46 AM
#4746   Michael Goser Sanofi Head of Lyopilization: bow-tie 10/19/17 02:58:27 PM
#4745   45,000 shares today I purchased. half of todays volume TheHungryHippo 10/19/17 02:47:11 PM
#4744   No sellers here. Hold em tight. ! TheHungryHippo 10/19/17 02:46:31 PM
#4743   No one listed here for Mymetics: 2018 speakers bow-tie 10/19/17 02:34:09 PM
#4742   $MYMX Bout time to get past that dime. MERCURIAL 10/19/17 01:58:49 PM
#4741   Read Vaccine Development Laboratory Talks about substantial Laboratory bow-tie 10/19/17 01:36:52 PM
#4740   Sanofi Top Executive: bow-tie 10/19/17 01:22:12 PM
#4739   Sanofi could give a decision soon. TheHungryHippo 10/19/17 01:01:53 PM
#4736   Looks like I got a good price again. Haven't Dubster watching 10/18/17 09:42:36 PM
#4735   I'm dealing w/ it Work Harder 10/18/17 09:11:16 PM
#4734   he's too retarded to do anything else.. He TheHungryHippo 10/18/17 09:09:49 PM
#4733   Not that it matters Work Harder 10/18/17 09:08:50 PM
#4732   Come on Sanofi$$$$ Get R Done ;} bow-tie 10/18/17 02:10:33 PM
#4731   Cmon Sanofi ! Lets do the deal! TheHungryHippo 10/18/17 01:36:05 PM
#4730   Got some again. Let it roll! Dubster watching 10/18/17 11:04:45 AM
#4729   Put your large block up at .0675 or MERCURIAL 10/18/17 10:48:31 AM
#4728   Your DD is thorough and invaluable. This board castaways 10/17/17 11:10:37 PM
#4727   I Know but too strong to even make tamtam84 10/17/17 08:44:26 PM
#4726   lol... thanks. TheHungryHippo 10/17/17 08:42:12 PM
#4725   AMEN HIPPO tamtam84 10/17/17 08:31:46 PM
#4724   I F***ing love you dude tamtam84 10/17/17 08:30:27 PM
#4723   U.S. Pediatric Vaccine Market expected to reach us bow-tie 10/17/17 05:04:18 PM
#4722   I'm French-Canadian ancestry came from Quebec Canada. Bow-tie bow-tie 10/17/17 04:05:31 PM
#4721   GuiNoir is a muscular black cat of French-Canadian GuiNoir 10/17/17 03:55:26 PM
#4720   Lol..... MADDSTACKER 10/17/17 03:50:46 PM
#4719   We will cleanse this stock of the retards TheHungryHippo 10/17/17 12:50:26 PM
#4718   LOL !!!!! TheHungryHippo 10/17/17 12:48:44 PM
#4717   Exactly! I don't really wanna average up...but I'd MERCURIAL 10/17/17 12:48:04 PM
#4716   Could take em out right now if we wanted. TheHungryHippo 10/17/17 12:45:04 PM